Determinant spreading and tumor responses after peptide-based cancer immunotherapy

Trends Immunol. 2003 Feb;24(2):58-61. doi: 10.1016/s1471-4906(02)00029-7.


Modern immunological assays are very sensitive for detection of antigen-specific T cells. These assays are used to detect increased levels of T cells after peptide-based immunotherapy for cancer in an attempt to describe surrogate endpoints correlated with anti-tumor activity. Recent reports demonstrate that determinant spreading develops in a high frequency of subjects with tumor regression responses after this type of immunotherapy and could be valuable for trial monitoring and the design of more effective vaccines.

Publication types

  • Review

MeSH terms

  • Cancer Vaccines / therapeutic use*
  • Clinical Trials as Topic / methods
  • Dendritic Cells / immunology
  • Epitopes
  • Humans
  • Neoplasms / immunology*
  • Neoplasms / therapy*
  • Peptides / immunology
  • T-Lymphocytes / immunology


  • Cancer Vaccines
  • Epitopes
  • Peptides